COMMUNIQUÉS West-GlobeNewswire

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
09/03/2026
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R Agonist) Toward [...]
Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
09/03/2026
- Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain [...]
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
09/03/2026
WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates
09/03/2026
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution [...]
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/03/2026
WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
09/03/2026
- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/03/2026
BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has [...]
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
09/03/2026
Initial MGC026 (B7-H3 ADC) Phase 1 results in mid-2026 Initial MGC028 (ADAM9 ADC) Phase 1 results in second half of 2026 Lorigerlimab Phase 2 LINNET study update in mid-2026 IND submission for MGC030, a first-in-class [...]
Stereotaxis Reports 2025 Full Year Financial Results
09/03/2026
ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth [...]
Xenon Pharmaceuticals Announces Proposed Public Offering
09/03/2026
VANCOUVER, British Columbia and BOSTON, MA, March 09, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical [...]
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
09/03/2026
NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH) (“Dianthus” or the “Company”), a clinical-stage biotechnology company dedicated to developing next-generation [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
09/03/2026
Please see enclosed pdf. Attachment 09032026_trading_in_shares_NBC
Kristen Boehmer of Empowered Lyfe Partners with MD Logic Health to Launch Daily Colostrum, an Advanced Low Molecular Weight Bioactive Colostrum
09/03/2026
Miami, FL, March 09, 2026 (GLOBE NEWSWIRE) -- As consumer awareness surrounding the connection between gut health and overall wellness continues to rise, demand for simple, high-quality, science-backed solutions is [...]
MemoTril Consumer Concerns Under Investigation: Critiquing The Memo Tril Claims
09/03/2026
A 2026 consumer research report examining MemoTril marketing claims, ingredient transparency, refund policies, manufacturing disclosures, and verification considerations for adults researching cognitive support [...]
FocusMax Cognitive Support Claims Evaluated: Latest 2026 Consumer Research Report on FocusMax Ingredients, Proprietary Blend Dosing, and Cognitive Supplement Research
09/03/2026
A 2026 informational consumer research report examining FocusMax cognitive support marketing claims, ingredient-level research context, proprietary blend transparency, pricing disclosures, and verification [...]
Choice Healthcare Services Announces Expansion of Children’s Choice Pediatric Dentistry Locations in California
09/03/2026
Two Locations to Launch New, Enhanced Offices in 2026 for Greater Patient Comfort and Accessibility Sacramento, CA, March 09, 2026 (GLOBE NEWSWIRE) -- Choice Healthcare Services , the parent company of Children’s Choice [...]
VisiFlora Gut-Eye Vision Support Claims Examined: 2026 Consumer Report on the 22-Ingredient Formula, Gut-Eye Axis Research, and What Adults Researching Vision Supplements Should Verify
09/03/2026
A 2026 informational consumer research report examining VisiFlora's gut-eye axis positioning, ingredient research context, 22-ingredient formula structure, pricing disclosures, and independent verification [...]
The Great Give Back brings community together in support of Royal Columbian Hospital
09/03/2026
NEW WESTMINSTER, British Columbia, March 09, 2026 (GLOBE NEWSWIRE) -- Royal Columbian Hospital Foundation is inviting the community to come together for The Great Give Back, presented by Pan American Silver , a free, [...]
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
09/03/2026
PARIS, FRANCE, 09 March 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik ® (tazemetostat) in all indications from all Ipsen markets. Ipsen’s decision to withdraw is [...]

Pages